Skip to main content
SpringerLink
Log in
Book cover

Advances in Bladder Research pp 371–386Cite as

Interferon Alpha for the Treatment of Superficial Bladder Cancer

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 462))

Abstract

The main problems that the patient with superficial transitional cell carcinoma (TCC) faces are the lifelong risk of tumor recurrence, and the risk of tumor progression and death secondary to cancer. Historically, cystectomy was the primary and only availible treatment option for patients who had recurrent bladder cancer or carcinoma in situ (CIS). However, the development of topical (intravesical) therapies for transitional cell carcinoma of the bladder has revolutionized the management of both superficial papillary tumors, and of flat carcinoma in situ. Due to the discovery of intravesical agents that have biologic activity against superficial TCC of the bladder (such as Bacillus Calmette-Guerrin (BCG) and Mitomycin), the mortality rate from bladder cancer has decreased despite a concurrent increase in the incidence of this malignancy.1

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nseyo UO, Lamm DL: Immunotherapy of Bladder Cancer. Seminars in Surgical Oncology 13:342–349, 1997.

    Article  PubMed  CAS  Google Scholar 

  2. Brosman SA: Bacillus Calmette-Guerin Immunotherapy. Urol Clin N.A. 19:557–564, 1992.

    CAS  Google Scholar 

  3. Lamm DL. Complications of Bacillus Calmette-Guerin Immunotherapy. Urol Clin N.A. 19:565–572, 1992.

    CAS  Google Scholar 

  4. Sargent ER, Williams RD: Immunotherapeutic Alternatives in Superficial Bladder Cancer. Urol Clin N.A. 19:581–589, 1992.

    CAS  Google Scholar 

  5. Zhang Y, Khoo HE, Esuvranthan K: Effects of Bacillus Calmette-Guerrin and Interferon alpha on Human Bladder Cancer in vitro. Int J Cancer 71: 851–57, 1997.

    Article  PubMed  CAS  Google Scholar 

  6. Borden EC, Groveman DS, Nasu T, Reznikoff C, and Bryan GT: Antiproliferative Activities of Interferons Against Human Bladder Carcinoma Cell Lines in vitro. J Urol 132:800–803, 1984.

    PubMed  CAS  Google Scholar 

  7. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996;46:5–27.

    Article  PubMed  CAS  Google Scholar 

  8. Herr HW, Schwalb DM, Zhang Z-F, Sogani PC, Fair WR, Whitmore WF, Jr, and Oettgen HF. Intravesical Bacillus Calmette-Guerin Therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol., 13:1404–1408, 1995.

    PubMed  CAS  Google Scholar 

  9. Heney NM: Natural History of Superficial Bladder Cancer.Urol Clin N.A. 19:429–433, 1992.

    CAS  Google Scholar 

  10. Sarosdy MF: Principles of Intravesical Chemotherapy and Immunotherapy. Urol Clin N.A. 19:509–519, 1992.

    CAS  Google Scholar 

  11. Utz DC, Hanash KA, Farrow GM: The Plight of the Patient with Carcinoma in situ of the Bladder. J Urol 103:160–4, 1970.

    PubMed  CAS  Google Scholar 

  12. Herr HW, Laudone VP, Badalament RA: Bacillus Calmette-Guerin Therapy Alters the Progression of Superficial Cancer. J Clin Oncol 6:1450–55, 1988.

    PubMed  CAS  Google Scholar 

  13. Franklin J, and Benson MC: New techniques in management and treatment of superficial bladder cancer. In Neal DE (ed.): Tumors in Urology. London, Springer-Verlag, pp 65–78, 1994.

    Chapter  Google Scholar 

  14. Lamm DL: BCG in Perspective: Advances in the treatment of superficial bladder cancer. Eur Urol., 27(Suppl):2–8, 1995.

    PubMed  Google Scholar 

  15. Berry DL, Blumenstein BA, Magyary DL: Local Toxicity Patterns Associated with Intravesical bacillus Calmette-Guerrin: A Southwest Oncology Group Study. Int J Urol 3:98–101, 1995.

    Article  Google Scholar 

  16. Isaacs A, and Lindenmann J: Virus inference: I. The interferon. Proc R Soc Lond (Biol), 147: 258–267, 1957

    Article  CAS  Google Scholar 

  17. Kurzrock R, Gutterman JU, and Talpaz M: Interferon-a,b,g: basic principles and preclinical studies. DeVita VT, Jr. et al. (Eds): Biologic Therapy of Cancer, p 247. Philadelphia, JB Linnincott Co., 1991.

    Google Scholar 

  18. Baron S, Tyring SK, Fleischmann R, Coppenhaver DH, Niesel DW, Kimpel GR, Stanton J, Hughes TK: The Interferons. Mechanism of Action and Clinical Applications. JAMA 266:1365–1381, 1991.

    Article  Google Scholar 

  19. Kurzrock R, Gutterman JU, and Talpaz M: Interferon-a,b,g: basic principles and preclinical studies. DeVita VT, Jr. et al. (Eds): Biologic Therapy of Cancer, p 247. Philadelphia, JB Linnincott Co., 1991.

    Google Scholar 

  20. Hawkyard S, James K, Prescott S, Jackson AM, Ritchie AWS, Smyth JF, Chisolm GD: The Effects of Recombinant Human Interferon-Gamma on a Panel of Uman Bladder Cancer Cell Lines. J Urol 145:1078–81, 1991.

    PubMed  CAS  Google Scholar 

  21. Molto L, Alvarez-Mon M, Carballido J, Manzano L, Guillen C, Prieto A, Olivier C, and Rodriguez-Zapata M: Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer, 70: 1247, 1994.

    Article  PubMed  CAS  Google Scholar 

  22. Patard J, Muscatelli-Groux B, Saint F, Popov Z, Maille P, Abbou C, Chopin D, et al. Evaluation of local immune response after intravesical bacille Calmette-Guerin treatemnt for superficial bladder cancer. Br. J. Urol. 78:709–714, 1996.

    Article  PubMed  CAS  Google Scholar 

  23. Tzai TS, Lin SN: Interferon alpha can alter the Lytic Susceptibility of Murine Bladder Transitional Cell Carcinoma (MBT-2) by Their Original Poor Specific Cytotoxic Tumor Infiltrating Lymphocytes. J Urol 146: 523/7, 1992.

    Google Scholar 

  24. Jackson AM, Alexandrov AB, Prescott S, James K, Chisolm GD: Expression of Adhesion Molecules by Bladder Cancer Cells: Modulation by Interferon-Gamma and Tumor Necrosis Factor. J Urol 148:1583, 1992.

    PubMed  CAS  Google Scholar 

  25. Alverez-Mon M, Molto LM, Manzano L, Olivier C, and Carballido JA: Immunomodulatory effect of inter-feron-a2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder. Anti-Cancer Drugs, 3(Suppl): 5, 1992.

    Article  Google Scholar 

  26. Molto L, Carballido J, Manzano L, Reyes E, Oliver C, Alvarez-Mon, M: Prophylactic Intracavitary Treatment with Interferon alpha Increases Interferon gamma production by Peripheral Blood Mononuclear Cells in Patients with Superficial Transitional Cell Carcinoma of the Bladder. Brit J Cancer 75:1849–53, 1997.

    Article  PubMed  CAS  Google Scholar 

  27. Fuchsberger N, Kubes M, Kontsek P, Borecky L, Hornak M, Godal A, Silvanova, Svec J: In vitro antiproliferative effect of interferon alpha in solid tumors: a potential predictive test. Neoplasma, 40: 293–6, 1993.

    PubMed  CAS  Google Scholar 

  28. Boccardo F, Cannata D, Rubagotti A, Guarnen D, Decensi A, Canobbio L Curotto A, Martorana G, Pe-goraro C, Selvaggi F, Salvia G, Comeri G, Bano A, Borella T, and Giuliani L: Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study. J Clin One, 12: 7, 1994.

    CAS  Google Scholar 

  29. Scorticatti C, de la Pena N, Bellora O, et al.: Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: pilot study. J Interferon Res., 2: 339–43, 1987.

    Article  Google Scholar 

  30. Ikic D, Nola P, Maricic Z, et al.: Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma. Lancet 1: 1022, 1981.

    PubMed  CAS  Google Scholar 

  31. Di Stasi SM, Virgili G, Vespasiani G, Porena M, and Micali F: Intralesional alpha interferon therapy in papillary superficial transitional cell carcinoma of the bladder: A pilot study. B J Urol., 71: 422, 1993.

    Article  Google Scholar 

  32. Koenig F, McGovern FJ: Fluorescence Detection of Bladder Carcinoma. Urology 50:778–9, 1997.

    Article  PubMed  CAS  Google Scholar 

  33. Ikic D, Nola P, Maricic Z, et al.: Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma. Lancet 1: 1022, 1981.

    PubMed  CAS  Google Scholar 

  34. Oliver R, Waxman J, Kwok H, et al.: Alpha lymphoblastoid interferon for non-invasive bladder cancer. Br J Cancer 53:432, 1986.

    Google Scholar 

  35. Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Farrari M, Hannigan J, Spiegel R, McWhirter K, and Freiha F: Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group Study. J Clin One, 6: 476, 1988.

    CAS  Google Scholar 

  36. Glashan RW: A randomized controlled study of intravesical a-2b-interferon in carcinoma in situ of the bladder. J Urol., 144: 658, 1990.

    PubMed  CAS  Google Scholar 

  37. Niijima T: Intravesical treatment of bladder cancer with recombinant human interferon-b. Cancer Immunol Immunoth., 30: 81, 1989.

    Article  CAS  Google Scholar 

  38. Geboers ADH, Van Bergen TNLM, and Ousterlinck W: Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer: J Urol 137:276A, abstract 691, 1987.

    Google Scholar 

  39. Geboers ADH, Van Bergen TNLM, and Ousterlinck W: Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer: J Urol 137:276A, abstract 691, 1987.

    Google Scholar 

  40. Migliari R, El Demiry M, Muscas G, and Usai E: Intravesical instillation of beta-interferon in the treatment of bladder cancer. Brit J Urol., 70: 169, 1992.

    Article  PubMed  CAS  Google Scholar 

  41. Kostakopoulos A, Deliveliotis Ch, Mavromanolakis E, Aravnatinos G, and Dimopoulos MA: Intravesical interferon alpha-2b administration in the treatment of superficial bladder cancer. Eur Urol., 18: 201, 1990.

    PubMed  CAS  Google Scholar 

  42. Bartoletti R, Massimini G, Criscuolo D, and Rizzo M: Interferon alpha 2a in superficial bladder cancer prophylaxis: Toleration and long-term follow-up. A phase I-II study. Anti-Cancer Res., 11: 2167, 1991.

    CAS  Google Scholar 

  43. Boccardo F, Cannata D, Rubagotti A, Guameri D, Decensi A, Canobbio L Curotto A, Martorana G, Pe-goraro C, Selvaggi F, Salvia G, Comeri G, Bano A, Borella T, and Giuliani L: Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study. J Clin One, 12: 7, 1994.

    CAS  Google Scholar 

  44. Boccardo F, Cannata D, Rubagotti A, Guameri D, Decensi A, Canobbio L Curotto A, Martorana G, Pe-goraro C, Selvaggi F, Salvia G, Comeri G, Bano A, Borella T, and Giuliani L: Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study. J Clin One, 12: 7, 1994.

    CAS  Google Scholar 

  45. Hoetl W, Hasun R, Albrecht W, Marberger M: How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer? Brit J Urol., 68: 495, 1991.

    Article  Google Scholar 

  46. Okamoto E, Kinne RKH, Sokeland J: Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C: J Urol 156:1492–95, 1996.

    Article  PubMed  CAS  Google Scholar 

  47. Kalbe T, Beer M, Mendoza E, Ikinger U, Link M, Reichert HE, Frangenheim T, Klein E, and Fabricius PG: BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe Ausgabe a, 33: 133–7, 1994.

    Google Scholar 

  48. Donovan MG, Grainger R, Hegarty JH, et al.: A prospective, randomized study of intravesical BCG and interferon in superficial bladder cancer. Presented as a poster at the 4th European Conf on Clinical Oncology and Cancer Nursing, Madrid 1987.

    Google Scholar 

  49. Jiminez-Cruz JF, Vera-Donoso CD, Leiva O, Pamplona M, Rioja-Sanz LA, Martinez-Lasierra MM, Flores N, Unda M: Intravesical Immunoprophylaxis in Recurrent Superficial Bladder Cancer (Stage T1): Multicenter Trial Comparing BCG and Interferon-Alpha. Urology 50:529–535, 1997.

    Article  Google Scholar 

  50. Portillo J, Martin J, Hernandez R, Correas M, Gutierrez J, Valle JD, Roca A, Vega A, Villanueva A, Gutierrez R: Results at 43 Months’ Follow-up of a Double Blind, Randomized, Prospective Clinical Trial Using Intravesical Interferon Alpha 2b in the Prophylaxis of Stage pT1 Trasitional Cell Carcinoma of the Bladder. Urology 49:187–190, 1997.

    Article  PubMed  CAS  Google Scholar 

  51. Lamm DL: Results at 43 Months’ Follow-up of a Double Blind, Randomized, Prospective Clinical Trial Using Intravesical Interferon Alpha 2b in the Prophylaxis of Stage pT1 Trasitional Cell Carcinoma of the Bladder (Editorial). Urology 49:190, 1997.

    Google Scholar 

  52. Engelmann U, Knopf H, Graff J, and the Project Group Bochum-interferon and superficial bladder cancer: Interferon-a2b instillation prophylaxis in superficial bladder cancer—a prospective, controlled three-arm trial. Anti-Cancer Drugs, 3: 33, 1992.

    Article  PubMed  Google Scholar 

  53. Ferrari P, Castagnetti G, Pollastri CA, Ferrari G, Tavoni F, Grassi D: Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: Interferon-a2b with epirubicin. Anti-Cancer Drugs, 3: 25, 1992.

    Article  PubMed  Google Scholar 

  54. Gomella LG, Keeley FX, Jr., McCue PA, and Lattime EC: A comparison of the local immune response to intravesical alpha-interferon and Bacillus Calmette-Guerin (BCG) in patients with superficial bladder cancer. J Urol., 151: 473A, 1994.

    Google Scholar 

  55. Downs T, Szilvasi, O’Donnel M: Pharmacological Biocompatibility between intravesical preparations of BCG and Interferon-Alfa 2B. J Urol 158:2311–2315, 1997.

    Article  PubMed  CAS  Google Scholar 

  56. Pagano F, Bassi P, Miiani C, Meneghini A, Maruzzi D, Garbeglio A: A Low Dose Bacillus Calmette-Guer-rin Regimen in Superficial Bladder Cancer Therapy: Is It Effective? J Urol 146:32–35, 1991.

    PubMed  CAS  Google Scholar 

  57. Strieker P, Pryor K, Nicholson T, Goldstein D, Golovsky D, Ferguson R, Nash P, Ehsman S, Rumma J, Mammen G, Penny R Bacillus Calmette-Guerin plus intravesical interferon alpha-2β in patients with superficial bladder cancer. Urology 48:957–961, 1996.

    Article  Google Scholar 

  58. O’Donnell MA, Chen X, Luo Y, DeWolf WC: Experimental and Clinical Evidence of Enhancement of BCG Efficacy by Adding Interferon-Alpha. J Urol 157:1502A, 1997.

    Google Scholar 

  59. O’Donnell MA: Personal Communication, 1998.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCLA Medical Center, Los Angeles, California, 90024-1782, USA

    John Naitoh & Arie S. Belldegrun

  2. Montefiore Medical Center, New York, New York, USA

    John Franklin

  3. Beth Isreal Hospital, Boston, Massachusetts, USA

    Michael A. O’Donnell

Authors
  1. John Naitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Franklin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael A. O’Donnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arie S. Belldegrun
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, University of California, San Francisco, USA

    Laurence S. Baskin  & Simon W. Hayward  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Naitoh, J., Franklin, J., O’Donnell, M.A., Belldegrun, A.S. (1999). Interferon Alpha for the Treatment of Superficial Bladder Cancer. In: Baskin, L.S., Hayward, S.W. (eds) Advances in Bladder Research. Advances in Experimental Medicine and Biology, vol 462. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4737-2_29

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4737-2_29

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7147-2

  • Online ISBN: 978-1-4615-4737-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation